Cencora Inc.
(NYSE:COR) on Wednesday reported third-quarter adjusted earnings of $4.48 per share, beating the consensus of $4.35.
The pharmaceutical solutions organization reported sales of $84.754 billion, up 5.1% year-over-year, beating the consensus of $84.315 billion, driven by steady demand across its health care distribution networks. • Cencora shares are powering higher.
Why is COR stock up today?
CEO Highlights Pharmaceutical Strategy and Growth Investments "Our third quarter results reflect the power of our pharmaceutical-centric strategy and the continued execution of our team members," said Robert Mauch, president and CEO of Cencora.
